Ofmit 8 mg Tablet

About Ofmit 8 mg Tablet

Ofmit 8 mg tablet is an anti-emetic medicine containing ondansetron. It is used to prevent nausea and vomiting caused by cancer chemotherapy, radiotherapy, or surgery. Doctors prescribe it to help manage these symptoms.

There are 74 brands of Ondansetron listed in Bangladesh. 12 of them have a lower unit price than Ofmit 8 mg. The lowest listed price is Periset 16 mg Suppository at ৳ 1 per unit.

What is Ofmit 8 mg Tablet?

Ofmit 8 mg is a tablet made by Nuvista Pharma Ltd. Its active ingredient is ondansetron, which belongs to a group of medicines called anti-emetics. It works by blocking a natural substance in the body that triggers the vomiting reflex. Doctors use it to prevent nausea and vomiting linked to cancer chemotherapy, radiotherapy, and operations. The tablet is available in an 8 mg strength and should be taken only as directed by a doctor. The dose and course are decided by the doctor for each person.

Uses of Ofmit 8 mg

Ofmit 8 mg is used to prevent nausea and vomiting that can happen with cancer chemotherapy and radiotherapy. It is also used to prevent and treat nausea and vomiting after surgery. It is not a general treatment for all types of nausea. Only a doctor can decide if it is suitable for a particular person and situation.

How to use Ofmit 8 mg

Take Ofmit 8 mg exactly as your doctor tells you. Swallow the tablet with water, with or without food. Do not change the dose or stop the course on your own. The doctor decides how often and for how long you take it. If you miss a dose, ask your doctor or pharmacist for advice. Keep the tablet out of reach of children.

Side effects of Ofmit 8 mg

Common side effects of ondansetron include headache, constipation and diarrhoea. Most of these are mild or moderate. Less common effects include a feeling of warmth or flushing, hiccups, and changes in liver enzyme tests. Rarely, serious allergic reactions, breathing problems, fast heartbeat, chest pain, and low potassium have been reported. Tell your doctor if you notice any side effect that worries you.

Safety and precautions

Do not take Ofmit 8 mg if you are allergic to ondansetron or any of its ingredients, or if you are taking apomorphine. Tell your doctor if you have liver problems, heart problems, or if you have had allergic reactions to similar medicines. It may hide signs of a bowel problem after abdominal surgery, so your doctor should be told about any surgery. There is not enough information about its use in pregnancy; ask your doctor before taking it if you are pregnant, planning to become pregnant, or breastfeeding.

Frequently asked questions

Who should avoid Ofmit 8 mg or ask the doctor first?

Do not take Ofmit 8 mg if you are allergic to ondansetron or any ingredient, or if you take apomorphine. Ask your doctor first if you have liver or heart problems, are pregnant or breastfeeding, or have had an allergic reaction to similar medicines.

What is Ofmit 8 mg used for and what kind of medicine is it?

Ofmit 8 mg is an anti-emetic. It is used to prevent nausea and vomiting caused by cancer chemotherapy, radiotherapy, or surgery. It works by blocking a substance in the body that triggers the vomiting reflex. It is not for everyday nausea; a doctor decides if it is right for you.

What does the dosage form and strength mean?

Ofmit 8 mg is a tablet, a solid form you swallow with water. The strength is 8 mg, meaning each tablet contains 8 mg of ondansetron. The dose and how often you take it are decided by your doctor, not by the strength alone.

How should I store Ofmit 8 mg?

Store Ofmit 8 mg at a temperature not exceeding 30°C in a dry place. Protect it from light and moisture. Keep the tablets out of reach of children. Do not use after the expiry date. Ask your pharmacist if you are unsure about storage.

Indications

Ondansetron is a serotonin subtype 3 (5-HT3) receptor antagonist indicated:
  • Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy.
  • Prevention and treatment of post-operative nausea and vomiting.
  • Prevention of radiotherapy-induced nausea and vomiting.

Pharmacology

Ondansetron is a potent, highly selective 5HT3 receptor-antagonist. Its precise mode of action in the control of nausea and vomiting is not known. Chemotherapeutic agents and radiotherapy may cause release of 5HT in the small intestine initiating a vomiting reflex by activating vagal afferents via 5HT3 receptors. Ondansetron blocks the initiation of this reflex. Activation of vagal afferents may also cause a release of 5HT in the area postrema, located on the floor of the fourth ventricle, and this may also promote emesis through a central mechanism. Thus, the effect of ondansetron in the management of the nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy is probably due to antagonism of 5HT3 receptors on neurons located both in the peripheral and central nervous system. The mechanisms of action in post-operative nausea and vomiting are not known but there may be common pathways with cytotoxic induced nausea and vomiting.

Dosage & Administration

Chemotherapy-Induced Nausea and Vomiting-
Adults, Pediatric patients (6 months to 18 years):
  • 8 mg tablet/orodispersible tablet: Three 0.15 mg/kg doses, up to a maximum of 16 mg per dose.
  • 4 mg orodispersible tablet: Three 0.15 mg/kg doses, up to a maximum of 16 mg per dose.
  • Injection: Three 0.15 mg/kg doses, up to a maximum of 16 mg per dose, infused intravenously over 15 minutes.
Radiotherapy-Induced Nausea and Vomiting-
Adults:
  • 8 mg tablet/orodispersible tablet: Initial Dose: 8 mg orally 1 to 2 hours before radiotherapy. Post Radiotherapy: 8 mg orally every 8 hours for up to 5 days after a course of treatment.
  • 4 mg orodispersible tablet: Three 0.15 mg/kg doses, up to a maximum of 16 mg per dose.
  • Injection: Three 0.15 mg/kg doses, up to a maximum of 16 mg per dose, infused intravenously over 15 minutes.
Postoperative Nausea and Vomiting-
Adults:
  • 8 mg tablet/orodispersible tablet: 16 mg given as two 8 mg tablets
  • 4 mg orodispersible tablet: 16 mg
  • Injection: 4 mg
Pediatrics (>40 kg): Injection: 4 mg
Pediatrics (40 kg): Injection: 0.1 mg/kg

Chemotherapy-induced Nausea and Vomiting-
Adults/Geriatric/Child of 12 years or over:
  • Highly emetogenic cancer chemotherapy: 30 ml (24 mg) Ondansetron Oral Solution administered 30 minutes before start of emetogenic chemotherapy.
  • Moderate emetogenic cancer chemotherapy: 10 ml (8 mg) Ondansetron Oral Solution administered 30 minutes before start of emetogenic chemotherapy. A further 10 ml dose should be administered after 8 hours of the first dose. One 10 ml dose should be administered twice a day (every 12 hours) for 1-2 days after completion of chemotherapy.
Pediatric (4-11 years): 5 ml (4 mg) Ondansetron Oral Solution should be taken 30 minutes before the start of chemotherapy. The other 2 doses should be taken 4 and 8 hours after the first dose. Then 5 ml oral solution should be administered 3 times a day (every 8 hours) for 1-2 days after completion of chemotherapy.


Oral solution:

Radiotherapy induced Nausea and Vomiting (Adults/Geriatric/Child of 12 years or over):
  • The recommended oral dosage: 10 ml (8 mg) Ondansetron Oral Solution 3 times daily.
  • For total body irradiation: 10 ml (8-mg) Ondansetron Oral Solution should be administered 1 to 2 hours before each fraction of radiotherapy administered each day.
  • For single high-dose fraction radiotherapy to the abdomen: one 10 ml Ondansetron Oral Solution should be administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after the first dose for 1 to 2 days after completion of radiotherapy.
  • For daily fractionated radiotherapy to the abdomen: 10 ml (8-mg) Ondansetron Oral Solution should be administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after the first dose for each day radiotherapy is given.
Postoperative Nausea and Vomiting (Adults/Geriatric/Child of 12 years or over):
  • 20 ml (16 mg) Ondansetron Oral Solution 1 hour before induction of anesthesia


Oral Soluble Film:

Prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy:
  • Adult oral dose: 24 mg given successively as three 8 mg films 30 minutes before the start of chemotherapy.
Prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy:
  • Adults and pediatric patients 12 years of age and older: One 8 mg film 30 minutes before chemotherapy followed by an 8 mg dose 8 hours later. Administer one 8 mg film twice a day (every 12 hours) for 1 to 2 days after completion of chemotherapy.
  • Pediatric patients 4 through 11 years of age: One 4 mg film three times a day. Administer the first dose 30 minutes before chemotherapy, with subsequent doses 4 and 8 hours later. Administer one 4 mg film three times a day (every 8 hours) for 1 to 2 days after completion of chemotherapy.
  • Prevention of nausea and vomiting associated with radiotherapy: The adult dosage is one 8 mg film three times a day.
  • Postoperative nausea and vomiting: The adult dose is 16 mg given successively as two 8 mg films 1 hour before anesthesia.

Interaction

Ondansetron does not itself appear to induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system of the liver. Because Ondansetron is metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes, inducers or inhibitors of these enzymes may change the clearance and hence, the half-life of Ondansetron. On the basis of available data, no dosage adjustment of Ondasetron is recommended for patients on these drugs.

Contraindications

Contraindicated in patients known to have hypersensitivity to the drug or any of its components. Concomitant use of apomorphine.

Side Effects

Frequently reported adverse events were headache, constipation and diarrhea, but the majority have been mild or moderate in nature. In chemotherapy-induced nausea and vomiting, rash has occurred in approximately 1% of patients receiving Ondansetron. There also have been reports to a sensation of flushing or warmth, hiccups and liver enzyme abnormalities. Rare cases of anaphylaxis, brochospasm, tachycardia, angina (chest pain), hypokalemia, shortness of breath have also been reported, except for bronchospasm and anaphylaxis, the relationship to Ondansetron is unclear. There have been no evidence to extrapyramidal reactions, in rare case oculogyric crisis appearing alone, as well as with other dystonic reactions without definitive clinical evidence. In case of PONV, with the exception of headache, rates of these events were not significantly different in the Ondansetron and placebo groups.

Pregnancy & Lactation

Carcinogenic effects were not seen in 2-year studies in rats and mice with oral Ondansetron doses up to 10 and 30 mg/kg per day, respectively. Ondansetron was not mutagenic in standard tests for mutagenicity. Oral administration of Ondansetron up to 15 mg/kg per day did not affect fertility or general reproduction performance of male and female rats.

Reproduction studies have been performed in pregnant rats and rabbits at daily oral doses up to 15 and 30 mg/kg per day, respectively, and have revealed no evidence of impaired fertility or harm to the fetus due to Ondansetron. There are, however, no adequate and well-controlled studies in pregnant women. Ondansetron is excreted in the breast milk of rats. So caution should be exercised when Ondansetron is administered to a nursing women.

Precautions & Warnings

Hypersensitivity reactions have been reported in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists. Ondansetron is not a drug that stimulates gastric or intestinal peristalsis. It should not be used instead of nasogastric suction. The use of Ondansetron in patients following abdominal surgery or in patients with chemotherapy-induced nausea and vomiting may mask a progressive ileus and/or gastric distension.

Storage Conditions

Store at temperature not exceeding 30ºC in a dry place. Protect from light and moisture.

Alternative brands of Ondansetron

Other brands with the same generic name, cheapest first.

See all 74 brands

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.